A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulmonary disease.

Trial Profile

A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulmonary disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs XEN D0501 (Primary)
  • Indications Chronic obstructive pulmonary disease; Cough
  • Focus Therapeutic Use
  • Sponsors Xention
  • Most Recent Events

    • 14 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Mar 2014 New source identified and integrated (European Clinical Trials Database)
    • 11 Feb 2014 This trial is expected to complete and results reported in quarter 3, 2014, according to an Ario Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top